相关临床试验
230
38 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1931
进行中（未招募）
3
1.3%
已完成
117
50.9%
尚未招募
35
15.2%
招募中
57
24.8%
终止
1
0.4%
Unknown
14
6.1%
撤回
1
0.4%
暂无批准数据
- Alpha Fusion and Curadh MTR announced a strategic partnership including a joint venture to advance global development of Astatine-211 based radiopharmaceuticals for cancer therapy. - The collaboration combines Alpha Fusion's At-211 drug discovery platform and early clinical work in Japan with Curadh's global radiopharmaceutical development expertise. - The joint venture will focus on clinical development of lead products in the US while building a broader pipeline of At-211 products using cyclotron production and GMP manufacturing. - Astatine-211's unique properties as a halogen emitter with short half-life position it as one of the most promising alpha particles for molecularly targeted cancer therapy.
- Researchers at Osaka University have developed a novel immune cell therapy specifically targeting acute myeloid leukemia (AML), potentially offering hope for patients who experience cancer recurrence after conventional treatments. - The therapy involves extracting immune cells from patients or umbilical cord blood, genetically modifying them to target only AML cells, multiplying them outside the body, and then administering them back to patients. - In preclinical studies, all six mice treated with the therapy survived for 140 days, and researchers are now preparing for clinical trials that could potentially cover approximately 150 cases annually.
